Amplitude Therapeutics, a private Boston-based biotechnology company, announced on August 19 a strategic research collaboration and licensing agreement with Eli Lilly and Company (NYSE: LLY) to discover and develop vaccines using Amplitude’s trans-amplifying RNA (taRNA) platform for infectious diseases. The companies did not name the specific diseases involved, describing the initial focus only as infectious disease vaccine programs with high unmet need, and Lilly holds an option to add up to two additional infectious disease targets to the collaboration later. Amplitude is privately held and does not trade under a stock ticker, so the direct investor relevance here runs through Lilly rather than Amplitude itself.

What Trans-Amplifying RNA Is

Trans-amplifying RNA is a further step in the evolution of RNA vaccine technology. The original mRNA vaccines, including the first COVID-19 shots, use a single RNA strand that simply encodes the target antigen. Self-amplifying mRNA vaccines improved on that by adding a second set of instructions, for an enzyme called a replicase, onto the same strand, so the RNA copies itself once inside a cell, extending and boosting antigen production from a smaller dose. Amplitude’s taRNA approach splits those two jobs onto two separate RNA molecules instead of one, keeping the replicase machinery on its own strand and the antigen instructions on another. The company says this separation makes it easier to swap in a new antigen or adjust the dose without having to re-engineer the replicase component each time, and that compared with other RNA vaccine formats, taRNA may enable higher potency, lower doses, and easier manufacturing; those are the company’s own stated advantages for the platform rather than data presented in this release.

How the Deal Is Structured

Under the agreement, Lilly receives exclusive, target-specific rights to develop and commercialize any licensed products that come out of the collaboration targets. Amplitude will lead taRNA optimization work and specific preclinical research activities under jointly agreed research plans, while Lilly takes on the rest: further preclinical development, clinical trials, manufacturing, regulatory filings, and eventual commercialization if any candidate gets that far. That division of labor is typical of platform-licensing deals between a smaller technology company and a large pharmaceutical partner, where the smaller company contributes early scientific work and the larger partner absorbs the far more expensive later-stage costs.

What Wasn’t Disclosed

Notably, this release does not disclose any financial terms. There is no upfront payment figure, no milestone payment structure, and no royalty rate mentioned anywhere in the announcement, which makes it impossible to size the deal’s potential value from this release alone. That is a meaningful gap for anyone trying to assess how significant this collaboration might be to Lilly’s broader pipeline or balance sheet, and no figures are estimated here.

What the Company Is Saying

Amplitude CEO Dr. Cory Sago described the company’s ambition as building a leading in vivo RNA platform by advancing both its taRNA and lipid nanoparticle (LNP) delivery technologies, and framed the Lilly collaboration as a chance to validate the taRNA platform across multiple vaccine programs while leveraging Lilly’s global development, manufacturing, and commercialization infrastructure. That is Sago’s own characterization of the deal’s strategic value rather than an independently confirmed assessment.

Amplitude’s Background

Founded in 2022, Amplitude describes itself as a member of the Lilly Gateway Labs community, a Lilly-affiliated incubator network, suggesting the two companies had an existing relationship before this formal agreement. Beyond infectious disease vaccines, Amplitude says it is applying its taRNA platform to protein replacement, immunology, and other genetic medicine applications, though none of those additional programs are part of this specific collaboration. The company’s investor base includes ARCH Venture Partners, Newpath Partners, and Alta Partners, established life sciences venture firms, and it has received non-dilutive funding from BARDA, CEPI, and the Gates Foundation, three organizations focused specifically on pandemic preparedness and global health rather than commercial return, which lends some independent credibility to the platform’s public health relevance beyond the company’s own marketing.

What’s Next

Vaccine-focused RNA platform deals like this one have become a recurring pattern in the pharmaceutical industry since mRNA technology proved itself during the COVID-19 pandemic, with large drugmakers generally preferring to license in next-generation delivery or RNA-design technology from smaller specialists rather than build every variant of the platform internally. For Lilly specifically, the deal adds an early-stage RNA vaccine platform to its infectious disease pipeline without the company having to build trans-amplifying RNA technology from scratch, though it is worth noting that at this stage the collaboration covers research and preclinical work only; no taRNA candidate arising from this partnership has entered human trials, and there is no guarantee any will reach that stage. This article covers a research collaboration and licensing agreement with no financial terms disclosed, and is not an investment recommendation.

Sources

Amplitude Therapeutics and Lilly Enter Strategic Collaboration to Develop Trans-Amplifying RNA Vaccines for Infectious Diseases, PRNewswire, August 19, 2026.

Editorial Disclosure

This article is based on a press release issued by Amplitude Therapeutics on August 19, 2026, distributed via PRNewswire. Amplitude Therapeutics is a privately held company and does not trade under a stock ticker; its collaboration partner, Eli Lilly and Company, trades on the New York Stock Exchange under the ticker LLY. BioTech Stocks Daily was not compensated for this coverage. Statements regarding the taRNA platform’s potential advantages and the strategic value of the collaboration are characterizations from Amplitude rather than independently verified findings; no financial terms of the agreement were disclosed, and no product from this collaboration has entered human clinical trials. This article is for informational and educational purposes only and does not constitute investment advice. See our full DISCLAIMER.